pyrazines has been researched along with Leukopenia in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors | Studies |
---|---|
Cash, T; Fox, E; Liu, X; Minard, CG; Reid, JM; Scheck, AC; Weigel, BJ; Wetmore, C | 1 |
Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
Caputo, S; Ghirlanda, G; Martini, F; Musella, T; Pitocco, D; Scavone, G; Zaccardi, F | 1 |
Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C | 1 |
Dalal, N; Kozolff, M; Nabhan, C; Starr, A; Tolzien, K; Villines, D | 1 |
Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
Berezin, F; Janisch, L; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
6 trial(s) available for pyrazines and Leukopenia
Article | Year |
---|---|
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Topics: Adolescent; Central Nervous System Neoplasms; Checkpoint Kinase 1; Checkpoint Kinase 2; Child; Child, Preschool; Female; Humans; Leukopenia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Thrombocytopenia; Young Adult | 2021 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Pyrazines; Rituximab; Treatment Outcome | 2012 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Pyrazines; Thrombocytopenia | 1994 |
3 other study(ies) available for pyrazines and Leukopenia
Article | Year |
---|---|
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Severe leucopenia associated with Sitagliptin use.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Leukopenia; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors | 2011 |